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In this issue of the Journal, Diacon and colleagues (pp. 943–953) assessed the 14-day 
extended early bactericidal activity (EBA) of pyrazinamide alone, clofazimine alone, and 
four combination regimens of bedaquiline in permutations with pyrazinamide, pretomanid 
(Pa824), and clofazimine (1). The positive treatment control was a standard regimen of 
rifampin, isoniazid, pyrazinamide, and ethambutol, delivered as a combination tablet 
(Rifafour; sanofi-aventis, Paris, France), and the study participants were treatment-naive 
patients with pulmonary tuberculosis with positive results from sputum-smear microscopy 
for acid-fast bacilli. On Day 14 of treatment, the pharmacokinetic (PK) parameters of the 
prescribed drugs alone and in combination were measured.
The results were clear-cut. First, each of the three experimental three-drug combinations 
(bedaquiline, pretomanid, and pyrazinamide; bedaquiline, pretomanid, and clofazimine; and 
bedaquiline, pyrazinamide, and clofazimine) and the one experimental four-drug 
combination (bedaquiline, pretomanid, pyrazinamide, and clofazimine) had extended EBA 
that was not significantly different from that of the Rifafour control regimen. Second, 
pyrazinamide alone had minimal EBA, as expected, and clofazimine alone provided no early 
activity at all. Third, the main PK parameters of each studied drug were apparently not 
affected by the other drugs given in combination; that is, drug–drug interactions were not 
apparent, and PK parameters were mostly within the expected range. For clofazimine, the 
peak plasma concentration after 14 days of daily administration was, on average, 0.2 μg/ml 
and close to its 0.25 μg/ml minimum inhibitory concentration for Mycobacterium 
tuberculosis. The peak plasma concentrations and 24-hour area under the concentration 
curve of bedaquiline, its M2 metabolite, and clofazimine varied six- to eightfold across 
regimens and among individuals, but the median exposures achieved were relatively similar 
across regimens; there was less variation in pretomanid and pyrazinamide exposures.
Such results are informative. Despite bedaquiline’s ability to shorten the time to culture 
conversion in patients with multidrug-resistant tuberculosis (2, 3) and in the mouse model 
(4), especially when combined with pyrazinamide (5), its potent bactericidal activity does 
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not become fully evident until 5–7 days have elapsed (6, 7). The present manuscript thus 
illustrates how this characteristic affects EBA of bedaquiline-containing combinations: none 
had a better EBA than the standard Rifafour combination. However, this observation applies 
only to the first 14 days of therapy. In longer-term studies, bedaquiline-containing 
combinations exert potent antimicrobial activity beyond the 14 initial days (2–4).
As a drug with delayed bactericidal activity, bedaquiline is in good company with 
pyrazinamide and rifampin, the drugs responsible for shortening standard tuberculosis 
treatment from 18 to 6 months. The relationship between EBA and later sterilizing activity is 
not obvious. Bactericidal drugs inflict lethal injury on actively replicating organisms during 
the initial days of treatment; this might not reflect or predict the more subtle metabolic 
inhibition induced by sterilizing activity later in therapy against nonreplicating bacilli (so-
called “dormant” or “persister” populations). This emphasizes a limitation of EBA 
evaluations (that they better reflect early “killing” activity against metabolically active 
bacilli, rather than later “sterilizing” efficacy against dormant bacilli); it also illustrates why 
the original EBA emphasis on the first 2 days of therapy (8) has been revised to extend to 7, 
then 14, and now 60 days of therapy as so-called serial sputum colony count studies (9). 
However, even the extended EBA cannot fully predict the outcome of a treatment that lasts 6 
or more months and engages a pathogen capable of marked metabolic modification in 
response to stresses (10).
A puzzling aspect of the current study is that the patients taking the control regimen, 
Rifafour, did not have a pronounced initial fall of colony-forming unit counts; this initial fall 
is historically considered the trademark of isoniazid alone or with other drugs (11). 
However, in the past, the same authors made a similar observation (12), whereas in another 
case, they did not (7). We and others have noted as well smaller baseline colony-forming 
unit counts in recent years in comparison with in the past. Whatever the cause, it emphasizes 
the natural variations in clinical microbiology, the questionable value of historical controls, 
and the caution with which EBA results should be interpreted.
Finally, a significant contribution of the current study is to demonstrate the total lack of EBA 
during Days 0–14 for clofazimine, despite administration of the drug with loading doses of 
300 mg on Days 1–3, followed by doses of 100 mg from Day 4 to Day 14. From their 
extensive PK investigation on the 14th day of treatment, the authors observed that the 
clofazimine plasma levels were quite variable from one patient to another; these levels were 
also close or slightly inferior on average to the minimum inhibitory concentration of 
clofazimine for M. tuberculosis. They speculated that the lack of EBA could result from 
insufficient free serum drug concentrations of clofazimine. Although this is a possibility, 
other explanations are also reasonable. Clofazimine does provide antituberculosis activity, as 
demonstrated in both clinical (13, 14) and experimental murine (15) studies. The simplest 
explanation for the lack of clofazimine EBA is that the drug, which is highly lipophilic, 
needs to accumulate to a certain level in the lipid-rich cell wall of M. tuberculosis before 
being able to reach the cell membrane, where it will disrupt the respiratory chain (16). 
Alternatively, bacterial intracellular energy stores might need to be depleted before the effect 
of the drug can be observed, as has been suggested for bedaquiline (7). In addition, reactive 
oxygen species, thought to be responsible for the antimicrobial effect of clofazimine (17), 
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might take time before inducing lethal mycobacterial DNA damage. Much work remains to 
be done to understand how and when clofazimine exerts its antimicrobial activity. In the 
meantime, clofazimine remains one of the group of potent antituberculosis drugs with little 
or no EBA. It is a merit of the work by Diacon and colleagues that it reminds us of the limits 
of the EBA approach: Potent EBA is valuable, but absent or limited EBA does not predict 
the absence of later antituberculosis activity reliably.
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